{"schema_version":"secwatch.filing_event.v1","accession":"0001804220-22-000029","form_type":"8-K","ticker":"REGN","cik":"0000872589","company_name":"REGENERON PHARMACEUTICALS, INC.","filed_at":"2022-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:53.803271+00:00","generated_at":"2026-06-22T10:50:25.047619+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Regeneron Q3 revenues down 15% to $2.94B; ex-REGEN-COV up 11%; EPS $11.66","bullets":["GAAP diluted EPS $11.66 (Q3 2021: $14.33); non-GAAP $11.14 ($15.37).","EYLEA U.S. net sales record $1.63B (+11% YoY); Dupixent global sales $2.33B (+40%).","Aflibercept 8 mg met primary endpoints in DME and wet AMD pivotal trials; BLA submission planned late 2022.","FDA granted EYLEA pediatric exclusivity through May 17, 2024; share repurchases $913M in Q3.","Full-year 2022 GAAP R&D guidance raised to $3.515-$3.600B; SG&A to $2.010-$2.090B."],"urls":{"canonical":"https://secwatch.observer/filing/0001804220-22-000029","json":"https://secwatch.observer/filing/0001804220-22-000029.json","markdown":"https://secwatch.observer/filing/0001804220-22-000029.md","text":"https://secwatch.observer/filing/0001804220-22-000029.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/872589/000180422022000029/0001804220-22-000029-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/872589/000180422022000029/regn-20221103.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T10:50:25.047619+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3536c8e0321f4beb75e5cbb642381f7c49211310","claim":"REGENERON PHARMACEUTICALS, INC. reported the quarter ended September 30, 2022 results: revenue $2.94 billion, net income $1,316 million, EPS $11.66.","evidence_excerpt":"EXHIBIT 99.1 Document Exhibit 99.1 Press Release Regeneron Reports Third Quarter 2022 Financial and Operating Results • Third quarter 2022 revenues decreased 15% to $2.94 billion versus third quarter 2021; excluding REGEN-COV ® (a)(b) , revenues increased 11% • Third quarter 2022 EYLEA ® U.S. net sales increased 11% versus third quarter 2021 to a record","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/872589/000180422022000029/0001804220-22-000029-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2022"},{"label":"Revenue","value":"$2.94 billion"},{"label":"Net income","value":"$1,316 million"},{"label":"EPS","value":"$11.66"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}